Instil Bio, Inc. (TIL) stock
TILNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.24−0.07 (-1.11%)
Close on Nov 12, 2026Market cap $42.32MP/E –Yield –
Earnings
Instil Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 12, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
–
Non-GAAP net loss per share, basic and diluted, Q2 FY2026
-$0.45
-$2.88 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Instil Bio's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 13, 2026during market hours | – | – | -$0.63 | -$0.45 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 15, 2026before the open | – | – | -$0.62 | -$0.32 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 27, 2026before the open | – | – | $1.21 | $0.97 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 13, 2025before the open | – | – | – | -$1.75 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 13, 2025before the open | – | – | -$3.24 | -$2.88 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 13, 2025before the open | – | – | -$4.32 | -$1.32 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 4, 2025before the open | – | – | -$1.82 | -$1.08 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 13, 2024before the open | – | – | -$3.54 | -$2.55 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024during market hours | – | – | $2.29 | $1.57 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 10, 2024before the open | – | – | $3.74 | $2.39 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 21, 2024during market hours | – | – | -$1.99 | -$1.26 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 13, 2023during market hours | – | – | -$0.52 | -$0.16 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 14, 2023before the open | – | – | – | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 11, 2023before the open | – | – | -$0.44 | -$0.41 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 31, 2023before the open | – | – | -$0.41 | -$0.36 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 14, 2022during market hours | – | – | -$0.43 | -$0.37 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 12, 2022before the open | – | – | -$0.46 | -$0.40 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 16, 2022before the open | – | – | -$0.42 | -$0.36 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 7, 2022before the open | – | – | -$0.43 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 12, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 13, 2021during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Instil Bio has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Instil Bio puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Instil Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- News
- Results
- Update
- Update
- Update
See a number that looks wrong?